The Food and Drug Administration Monday authorized the emergency use of two new products designed to respond to the COVID-19 ventilator shortage. FDA approved the NASA’s second VITAL ventilator.

Like NASA’s first iteration of the device, VITAL is designed to last three-to-four months using components sourced from outside the current medical device supply chain. Unlike NASA’s first ventilator, VITAL uses an internal compressor as its energy source, rather than wall gas.

Meanwhile, the Fitbit Flow earned an FDA emergency use authorization as an emergency resuscitator. The Fitbit Flow is a continuous respiratory support system that includes an FDA-cleared, Ambu-designed manual resuscitator bag with audible and visual alarms.

By pairing the actuator with a manual resuscitator, health care professionals can use the device to support patients’ respiratory needs when no FDA-cleared clinical ventilators are available.

Related News Articles

Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…
Headline
The Centers for Disease Control and Prevention's COVID-19 data tracker shows an 18.1% test positivity rate for the week ending Aug. 10, the highest it has been…
Headline
The Centers for Disease Control and Prevention Aug. 13 issued an advisory alerting of an uptick of cases of parvovirus B19 across the U.S. Parvovirus B19 is a…
Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…